<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3217">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01964001</url>
  </required_header>
  <id_info>
    <org_study_id>CF13197</org_study_id>
    <nct_id>NCT01964001</nct_id>
  </id_info>
  <brief_title>The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <authority>Taiwan: Ministry of Health and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carcinoma is the leading cause of worldwide. Hepatocellular carcinoma (HCC) is the second
      cause of cancer mortality in Taiwan. Vitamin B-6 and coenzyme Q10 has been recognized as
      antioxidants and anti-inflammatory nutrients in recent clinical studies. The purposes of
      this study are going to investigate the relation of vitamin B-6 and coenzyme Q10 with the
      indicators of oxidative stress, antioxidant enzymes activities and the inflammatory markers
      in patients with stage 1 and stage 2 HCC. The study is designed as an intervention study.
      The investigators will recruit HCC patients with stage 1 and stage 2 (n = 150) who are
      identified by liver biopsy. HCC subjects are randomly assign to placebo, vitamin B-6 (50
      mg/d), coenzyme Q10 (300 mg/d), and vitamin B-6 plus coenzyme Q10 supplements groups.
      Intervention is going to administration for three months. The concentrations of vitamin B-6,
      coenzyme Q10, oxidative stress indicators, antioxidant enzymes activities, antioxidant
      vitamins (vitamin A and E), and inflammatory markers are going to be analyzed. The results
      would provide more information nutrients for clinical physicians and dietitians for
      considering suggesting patients with HCC using vitamin B-6 or coenzyme Q10 supplementation
      to improve their clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Antioxidant capacity</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study are going to measure the indicators of antioxidant capacity including Vitamin B-6, coenzyme Q10, vitamin A and E, lipid peroxidation markers (malondialdehyde), and antioxidant enzymes activities (catalase, glutathione peroxidase and superoxide dismutase).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation markers</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study are going to measure the inflammation markers including C-reactive protein, Tumor necrosis factor-alfa, Interleukin-1 beta, Interleukin-6,adiponectin, homocysteine, S-adenosyl-methionine, and S-adenosyl-homocysteine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatocellular Carcinoma.</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>starch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B-6</intervention_name>
    <description>Vitamin B-6 50 mg/d</description>
    <arm_group_label>Dietary supplements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>Coenzyme Q10 300 mg</description>
    <arm_group_label>Dietary supplements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B-6+Coenzyme Q10</intervention_name>
    <description>Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)</description>
    <arm_group_label>Dietary supplements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>starch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - The HCC patients with stage 1 and stage 2 (n = 150) who are identified by liver biopsy.

        Exclusion Criteria:

          -  age &lt; 20 years old.

          -  The patients who had heart, renal, gestational, diabetes, or other metabolic
             diseases.

          -  Under the medications which may interfere the vitamin B-6 or coenzyme Q10
             concentrations, such as phenobarbital, phenytoin, cycloserine, pyrazinamide,
             isoniazid, (thio)semicarbazide, hydramitrazine, phenelzine, carbidopa, levodopa,
             hydralazine, steroids, penicillamine, ,Statin, or Warfarin.

          -  The women who are during pregnancy or Lactation.

          -  The women who are taking the oral contraceptives.

          -  The subjects who are taking the dietary supplements, such as vitamin B-6, coenzyme
             Q10, or other antioxidant vitamins.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ping-Ting Lin, Ph.D.</last_name>
    <phone>+886-4-24730022</phone>
    <phone_ext>12187</phone_ext>
    <email>apt810@csmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taichung Verterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping-Ting Lin, Ph.D.</last_name>
      <phone>+886-24730022</phone>
      <phone_ext>12187</phone_ext>
      <email>apt810@csmu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Hsiao-Tien Liu, M.D.</last_name>
      <phone>+886-23592525</phone>
      <phone_ext>5021</phone_ext>
      <email>langhsky@vghtc.gov.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ping-Ting Lin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
